-
Medicenna Presents at National Brain Tumor Society’s Research Round Table
25 Jul 2023 11:26 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Presents at National Brain Tumor Society's Research Round Table
25 Jul 2023 11:00 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update
25 Feb 2025 12:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Clinical trial approved by FDA for glioblastoma brain cancer
16 Mar 2022 01:45 GMT
… recurrent glioblastoma, a type of brain cancer. The phase I trial is … of the IL-4 and IL-13 cytokine receptor complex. This therapeutic …
-
Discoid Domain Receptors Signaling in Macrophages-Mediated Diseases
19 Feb 2025 16:22 GMT
… activated by IL-4 or IL-13 to attenuate inflammatory responses and … -1 tyrosine kinase in human brain tumors. Neurosurgery. 2000;47(6):1400 …
-
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
17 Apr 2023 11:00 GMT
… characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and … ability of our IL-13 Superkines to preferentially … Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine … uniformly fatal form of brain cancer. Bizaxofusp has obtained …
-
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
13 Feb 2025 15:28 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
05 Feb 2025 12:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022
22 Sep 2022 11:30 GMT
… cancer
--IL-4/IL-13 Super-antagonist displayed monotherapy activity … domain linked to wild type IL-13. This superior binding profile … inhibit IL-4/IL-13 mediated functions as measured by … and uniformly fatal form of brain cancer. MDNA55 has obtained Fast …
-
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting
12 Apr 2021 11:00 GMT
… The IL-2/IL-13 dual specific cytokine selectively stimulates … , an IL-2/IL-13 dual specific cytokine derived from … agonist (MDNA19) linked to an IL-13 super-antagonist (MDNA413). Data … and uniformly fatal form of brain cancer. MDNA55 has been studied …
About
© 1995-2025